nirsevimab-alip
Infant RSV Hospitalization Rates Dropped Significantly After Antibody, Vaccine Prevention Introduced
RSV-associated hospitalization in infants fell sharply during the first virus season after the introduction of ...
JUNE 5, 2025
Nirsevimab Highly Effective in Preventing Hospitalizations
Interim data from the CDC show that Beyfortus is highly effective in reducing infants’ risk for ...
MAY 15, 2024
CDC, FDA Expedite Additional Doses of Beyfortus for Infants
The CDC announced 77,000 additional doses of nirsevimab-alip, a long-acting monoclonal antibody designed to protect ...
NOVEMBER 16, 2023
Load more